Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Up 76.7% in April

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 4,010,000 shares, a growth of 76.7% from the March 31st total of 2,270,000 shares. Based on an average trading volume of 2,450,000 shares, the short-interest ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AQST. Piper Sandler began coverage on shares of Aquestive Therapeutics in a research note on Thursday, April 11th. They issued an “overweight” rating and a $10.00 price objective for the company. Raymond James initiated coverage on shares of Aquestive Therapeutics in a research report on Thursday, March 28th. They set an “outperform” rating and a $7.00 price objective for the company. JMP Securities raised their target price on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a report on Friday, March 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Friday, April 5th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $8.00.

Insider Activity

In other news, insider Alexander Mark Schobel sold 50,000 shares of the firm’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.00, for a total transaction of $300,000.00. Following the sale, the insider now owns 984,476 shares in the company, valued at approximately $5,906,856. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 8.39% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Jump Financial LLC acquired a new position in shares of Aquestive Therapeutics in the 4th quarter valued at $60,000. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Aquestive Therapeutics by 14.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock worth $379,000 after buying an additional 30,898 shares during the period. PFG Investments LLC acquired a new position in Aquestive Therapeutics during the 1st quarter valued at $204,000. Legato Capital Management LLC acquired a new position in Aquestive Therapeutics during the 4th quarter valued at $688,000. Finally, Acadian Asset Management LLC raised its stake in shares of Aquestive Therapeutics by 238.8% in the 3rd quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock valued at $841,000 after buying an additional 388,017 shares in the last quarter. 32.45% of the stock is owned by institutional investors and hedge funds.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock traded up $0.14 during midday trading on Friday, reaching $4.07. The company’s stock had a trading volume of 2,986,647 shares, compared to its average volume of 2,312,568. Aquestive Therapeutics has a fifty-two week low of $1.19 and a fifty-two week high of $6.23. The stock’s 50 day simple moving average is $4.17 and its 200 day simple moving average is $2.81.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). The firm had revenue of $13.21 million for the quarter, compared to the consensus estimate of $11.79 million. As a group, analysts predict that Aquestive Therapeutics will post -0.36 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.